Metabolism of remimazolam in primary human hepatocytes during continuous long-term infusion in a 3-D bioreactor system

BACKGROUND: Remimazolam is an ultra-short acting benzodiazepine under development for procedural sedation and general anesthesia. It is hydrolyzed by CES1 to an inactive metabolite (CNS7054). PURPOSE: In this study, the effect of continuous remimazolam exposure on its metabolism and on CES1 expressi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Drug Des Devel Ther
Hlavní autoři: Freyer, Nora, Knöspel, Fanny, Damm, Georg, Greuel, Selina, Schneider, Christin, Seehofer, Daniel, Stöhr, Thomas, Petersen, Karl-Uwe, Zeilinger, Katrin
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2019
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6450186/
https://ncbi.nlm.nih.gov/pubmed/31037028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S186759
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky